Fig. 2: Siglec-8 mAb treatment reduces acute BLM-induced lung inflammation and fibrosis. | Mucosal Immunology

Fig. 2: Siglec-8 mAb treatment reduces acute BLM-induced lung inflammation and fibrosis.

From: A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation

Fig. 2

a Schematic of acute BLM-induced lung fibrosis model. b Total leukocytes, c Neutrophils, d monocytes, e macrophages, f IL-6, g CXCL1, and h IP-10 in BAL fluid of sham (black), ISO + acute BLM (gray), or anti-S8 + acute BLM (blue) treated mice. i Ashcroft scores of lung fibrosis and BAL fluid levels of j collagen, and k TGFβ in sham (black), ISO + acute BLM (gray), or anti-S8 + acute BLM (blue) treated mice. Data are plotted as mean ± SEM (10–14 mice/group) and are representative of at least three experiments. **P < 0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA with Tukey’s multiple-comparisons test. BAL bronchoalveolar lavage, BLM bleomycin, ISO isotype control.

Back to article page